| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $285.9M | +15.0% |
| SG&A Expense | $71.6M | +42.0% |
| Operating Income | -$272.6M | +23.6% |
| Net Income | -$269.5M | +24.3% |
| EPS (Basic) | -$1.43 | +33.2% |
| EPS (Diluted) | -$1.43 | +33.2% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $176.8M | -30.1% |
| Short-term Investments | $247.2M | -17.0% |
| Current Assets | $444.4M | -20.4% |
| Total Assets | $822.7M | -27.2% |
| Current Liabilities | $111.5M | +12.4% |
| Total Liabilities | $323.4M | -19.3% |
| Stockholders' Equity | $499.3M | -31.5% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$290.1M | -15.5% |
| Capital Expenditures | $20.9M | -30.1% |
| Investing Cash Flow | $210.6M | +185.7% |
| Financing Cash Flow | $4.9M | -99.2% |
| Free Cash Flow | -$310.9M | -10.7% |